Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
| Revenue (TTM) | 742,000 |
| Gross Profit (TTM) | $-1.30B |
| EBITDA | $-1.62B |
| Operating Margin | 0.00% |
| Return on Equity | -79.10% |
| Return on Assets | -30.10% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $7.49 |
| Price-to-Book | 16.75 |
| Price-to-Sales (TTM) | 9035.10 |
| EV/Revenue | 8370.02 |
| EV/EBITDA | -9.71 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -95.20% |
| Shares Outstanding | $214.34M |
| Float | $184.45M |
| % Insiders | 1.88% |
| % Institutions | 100.91% |
Volatility is currently contracting
Revolution Medicines (NASDAQ:RVMD | RVMD Price Prediction) closed at $205.55 on August 11, 2026, giving the pre-commercial oncology platform a market cap of $44.1 billion.
SAN CARLOS, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution.
Revolution Medicines is evolving from a clinical-stage biotech to a near-term commercial oncology player, anchored by its RAS(ON) inhibitor platform. RVMD's robust $3.9 billion cash position and additional committed capital support aggressive pipeline expansion and commercial launch readiness, reducing near-term dilution risk. Daraxonrasib's potential FDA approval and commercial launch in pancreatic cancer could fundamentally transform RVMD's financial profile and validate its broader RAS-targeted strategy.
Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.
Revolution Medicines NASDAQ: RVMD said its second-quarter 2026 results reflected continued investment in late-stage cancer programs, commercial launch preparations and manufacturing capacity as it advances daraxonrasib and other RAS-targeted therapies across pancreatic and lung cancer.
REDWOOD CITY, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2026, and provided an update on corporate progress.
REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, after market close. At 4:30 p.m. ET that day (1:30 p.m. PT), members of Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.
Revolution Medicines' FDA filing for daraxonrasib in metastatic pancreatic cancer enters an accelerated review program, bringing its first commercial product closer.
REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) accepted for review the company's New Drug Application (NDA) for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review of data on daraxonrasib, the company's investigational RAS(ON) multi-selective inhibitor. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases as they become available, ahead of the submission of a full marketing authorization application. Daraxonrasib was designated by the EMA as an orphan medicinal product for the treatment of pancreatic cancer and has been recognized as a high priority under EMA's Cancer Medicines Pathfinder project based on its potential to address a high unmet medical need.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RVMD and any ticker you trade — then tracks every position and per-strategy win rate.
